Botaneco validates oleosome based sunscreen formulation

June 28, 2010 - Calgary, Alberta - Botaneco Specialty Ingredients Inc. is pleased to announce today that its oleosome based sunscreen formulation, in a recent sunscreen panel test, exhibited far higher in-vivo SPF values(30+) than was expected. The 20 person panel (which is required by the FDA before an SPF value can be claimed) builds on previous work carried out with smaller panels. The prototype formulation which tested at SPF30+, contained a total of 2.5% active ingredients and represents significant potential cost savings compared to marketed formulations of similar SPF 30 rating, which typically contain much higher actives levels (15-20%). Dr. Jack Guth, Vice President R&D notes that “because the larger panel size allows us to meet the requirements of the FDA sunscreen monograph, finished goods manufacturers can now market our oleosome based sunscreen formulation and claim SPF 30 protection”. In addition to potential cost savings, there may be safety implications to using formulations with reduced actives.

About Botaneco Specialty Ingredients Inc.
Botaneco is the global developer and marketer of innovative Oleosome-based ingredients to the personal care and OTC topical markets. As a technologically driven provider of high performance, proprietary ingredients, Botaneco is committed to developing innovative materials that offer multifunctional, tangible and documented benefits to both formulators and consumers. Botaneco’s head office and manufacturing facility is located in Calgary, Canada and its satellite office in Bensalem, PA. More information is available and can be accessed at www.botaneco.ca.


For further information contact:
Botaneco Specialty Ingredients Inc.
Mike Stangel
President and CEO
215-604-0631
stangelm@botaneco.ca
NEWS | ABOUT | TEAM | INVESTMENT CRITERIA | PORTFOLIO | CONTACT




Botaneco validates oleosome based sunscreen formulation

June 28, 2010 - Calgary, Alberta - Botaneco Specialty Ingredients Inc. is pleased to announce today that its oleosome based sunscreen formulation, in a recent sunscreen panel test, exhibited far higher in-vivo SPF values(30+) than was expected. The 20 person panel (which is required by the FDA before an SPF value can be claimed) builds on previous work carried out with smaller panels. The prototype formulation which tested at SPF30+, contained a total of 2.5% active ingredients and represents significant potential cost savings compared to marketed formulations of similar SPF 30 rating, which typically contain much higher actives levels (15-20%). Dr. Jack Guth, Vice President R&D notes that “because the larger panel size allows us to meet the requirements of the FDA sunscreen monograph, finished goods manufacturers can now market our oleosome based sunscreen formulation and claim SPF 30 protection”. In addition to potential cost savings, there may be safety implications to using formulations with reduced actives.

About Botaneco Specialty Ingredients Inc.
Botaneco is the global developer and marketer of innovative Oleosome-based ingredients to the personal care and OTC topical markets. As a technologically driven provider of high performance, proprietary ingredients, Botaneco is committed to developing innovative materials that offer multifunctional, tangible and documented benefits to both formulators and consumers. Botaneco’s head office and manufacturing facility is located in Calgary, Canada and its satellite office in Bensalem, PA. More information is available and can be accessed at www.botaneco.ca.


For further information contact:
Botaneco Specialty Ingredients Inc.
Mike Stangel
President and CEO
215-604-0631
stangelm@botaneco.ca